Navigation Links
Pervasis to Present Interim Data from Phase 1/2 Clinical Study of Novel Cell Therapy Targeting Peripheral Artery Disease at International Conference on Cell Therapy for Cardiovascular Diseases
Date:1/20/2011

CAMBRIDGE, Mass., Jan. 20, 2011 /PRNewswire/ -- Pervasis Therapeutics, Inc. today announced it will present interim data from the company's Phase 1/2 clinical study of PVS-10200, an investigational cell-based therapy under development to prevent restenosis in patients with peripheral arterial disease (PAD) who undergo an angioplasty and stent procedure in the superficial femoral artery. Jean-Marc Alsac, MD, Associate-Faculty in Vascular Surgery, Department of Cardiovascular Surgery, Hopital Europeen Georges Pompidou, Paris, and principal investigator of the study, will present the findings at the Sixth Annual International Conference on Cell Therapy for Cardiovascular Disease (IC3D) today in New York City.

Dr. Alsac will report initial 6-month data from the open-label dose escalation study designed to evaluate the safety, feasibility and impact of PVS-10200 on the incidence of major adverse events. Secondary endpoints include the rates of target lesion revascularization, primary patency and restenosis.  In June 2010, Pervasis announced the first cohort of patients had been fully enrolled in the study. Enrollment in a second cohort is ongoing.  The study is being conducted at Hopital Europeen Georges Pompidou, and two other hospitals in France, Hopital Bichat and Centre Hospitalier Universitaire d'Amiens.

"Although most revascularization procedures of the superficial femoral artery have high initial success rates, restenosis is a common occurrence within a year after surgery, leading to poor outcomes and the need for repeat procedures," said Dr. Alsac. "I am highly encouraged by the initial findings of the study. The low rate and nature of adverse events reported thus far demonstrate the potential of PVS-10200 as a safe, viable and minimally invasive option to treat vascular injury and improve outcomes for patients."

Pervasis is a clinical stage company focused on developing breakthrough therapies with the potential to improve outcom
'/>"/>

SOURCE Pervasis Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Pervasis Therapeutics Receives FDA Clearance for Pivotal Phase 3 Trial of Vascugel(R)
2. Pervasis Therapeutics Awarded Four Grants Under the Qualifying Therapeutic Discovery Project
3. Pervasis Therapeutics to Develop Novel Cell-Based Approach to Target Tumor Environment, Prevent Cancer Recurrence
4. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
5. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
6. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
7. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
8. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
9. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
10. Pre-clinical Data on Recent Advances with HIV VLP Vaccine Presented at AIDS Vaccine 07 Conference
11. Iomai Announces Data from Phase 2 Field Study of Travelers Diarrhea Vaccine Accepted for Presentation at ICAAC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014 The Cadence Fitness & Health Center has ... Medical Fitness Association, a non-profit organization assisting medically integrated ... The Cadence Fitness & Health Center is the only ... in the Chicagoland area. "The certification means ...
(Date:1/15/2014)... YORK , Jan. 15, 2014 ... report is available in its catalogue: ... for Advanced Drug Delivery Systems -- Focus ... STUDY OBJECTIVES ...
(Date:1/14/2014)... (Nasdaq: LMNX ) today announced that it expects ... Monday, February 3, 2014. A press release announcing the results ... (Logo: http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO ) Management will ... financial results for the fourth quarter and twelve months ended ...
Breaking Medicine Technology:Cadence Fitness & Health Center Certified as Medical Fitness Facility 2Cadence Fitness & Health Center Certified as Medical Fitness Facility 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3
... 10, 2011 Life is unpredictable and can be even ... season, your runny nose, sneezing or itchy, watery eyes just ... Adventures contest on Facebook.  Allergy sufferers are invited to ... for a chance to win $5,000 toward a fun-filled adventure ...
... JACKSONVILLE, Fla., Aug. 10, 2011 MSC Care Management, ... care management solutions to the workers, compensation industry, introduces ... to help our customers manage patient care progress and ... to MSC customers, targets vital patient feedback on the ...
Cached Medicine Technology:Allegra® and Survivor Winner Danni Boatwright Want to Hear About Your "Allergy Adventures" 2Allegra® and Survivor Winner Danni Boatwright Want to Hear About Your "Allergy Adventures" 3Allegra® and Survivor Winner Danni Boatwright Want to Hear About Your "Allergy Adventures" 4MSC Monitors Patient Benchmarks on Behalf of Customers with MSC CareTrack 2
(Date:4/17/2014)... have identified the first genetic variant specifically associated ... accounting for around 10-15 per cent of all ... of the breast cancer sub-type, called invasive lobular ... causes of this particular kind of breast cancer, ... research, published today (Thursday) in the journal ...
(Date:4/17/2014)... to a study published today in PLOS Pathogens ... where malaria is common can mount an immune response ... to avoid repeated bouts of high fever and illness ... their bloodstream. The findings may help researchers develop future ... the malaria parasite. , Each year, approximately 200 million ...
(Date:4/17/2014)... Two recent papers by a University of Colorado ... scientists develop treatments or vaccines for Dengue fever, ... other disease-causing flaviviruses. , Jeffrey S. Kieft, PhD, ... the School of Medicine and an early career ... colleagues recently published articles in the scholarly journals ...
(Date:4/17/2014)... Northwestern University synthetic biology team has created a ... programmable therapeutics that could travel the body and ... , Engineering cell-based, biological devices that monitor and ... clinical synthetic biology. However, no existing technology enabled ... patient,s physiological state and respond in a customized ...
(Date:4/17/2014)... that as many as 10 million older Americans suffer ... and isolation. , However, new research a project ... Americans for six years found that Internet use ... by more than 30 percent. , "That,s a very ... professor of telecommunication, information studies and media who led ...
Breaking Medicine News(10 mins):Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 2Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 3Health News:Study sheds light on how the immune system protects children from malaria 2Health News:CU researchers discover target for treating dengue fever 2Health News:Building 'smart' cell-based therapies 2Health News:Internet use can help ward off depression among elderly 2
... A form of partial epilepsy associated with auditory and ... of brain development during early childhood, according to a ... Center (BIDMC). , Described in today,s Advance On-line issue ... the first genetic link between childhood brain development and ...
... can lessen stress when children get overwhelmed, experts say ... are nervous about the new school year can relax ... Experts at Duke University, in Durham, N.C., recommend mindfulness, ... children transition into the new school year and deal ...
... ... of Washington D.C. is business owner John Wahlquist of eMedicalSystems, Bremerton, Washington state. Author of ... unusual choice to retire his product and migrate his medical practices over to a new ... ...
... ... Reproduction Agency , ... (PRWEB) August 23, 2009 -- Steve Masler, CEO of The Donor Source International, LLC, a ... Donor Source of New England, that will focus on the New England Third-Party Reproduction market., ...
... , LOUISVILLE, Ky., Aug. 22 A top medical ... Legion and colleague veterans service organizations can play a key role ... national suicide prevention coordinator, in pointing to the 5,000 self-inflicted deaths ... of our responsibility to own up to that. There,s no reason ...
... poor prognosis in both blacks and whites after surgery, study ... the risk of prostate cancer recurrence in both black and ... suggesting obesity may be more significant for black men. , ... study senior author Dr. Stephen Freedland, an associate professor of ...
Cached Medicine News:Health News:Fragile period of childhood brain development could underlie epilepsy 2Health News:Soothe Back-to-School Anxiety, Teach Kids to Relax 2Health News:eMedical Systems, Inc. Selects MPMsoft as its Medical Billing Software Solution 2Health News:eMedical Systems, Inc. Selects MPMsoft as its Medical Billing Software Solution 3Health News:The American Legion Can Play Key Role in Vets' Suicide Prevention, Says VA 2Health News:Obesity Tied to Prostate Cancer Recurrence 2
Low pressure automatic tourniquet with manual time. Includes extension hose and spiral replacement hose....
... Safety. Convenience. Reliability. Cost. These are the ... personnel, and administrators. With a special focus ... practical elements of todays technology to develop ... The A.T.S. 2000 Tourniquet uses ambient air ...
... Retractor System has been designed so the ... delicate soft tissue away from the operative ... the procedure without stay-sutures or assistance. This ... the freedom to do other tasks, which ...
... Battery System is a revolutionary new addition ... surgical instruments. The PowerPro Battery System is ... powered instrument available on the market. It ... designed to meet the requirements of large ...
Medicine Products: